[Changes in biochemical inflammation markers in evaluation of the effectiveness of basic chemotherapy in bronchial asthma].
OBJECTIVE
To analyse informative value of monitoring of NO metabolites concentration in condensate of expired air vapor (EAVC) for definition of bronchial asthma (BA) severity and antiinflammatory effect of basic therapy.


METHODS
NO metabolites concentration in EAVC was measured with Grace's reagent in 76 adults and 180 children in the course of basic therapy with flixotide, tailed, ketotiphen with intal.


RESULTS
NO metabolites occurred in high concentrations in EAVC of both children and adults. These concentrations were the highest in attacks and in severe BA and were reduced by basic therapy. This effect differed with the drug and its dose, e.g. flixotide and tailed given to children for a month reduced NO metabolites close to concentrations observed in healthy subjects. Ketotiphen and intal for 6 months failed to low NO metabolites significantly.


CONCLUSIONS
NO secretion monitoring is sensitive in assessment of respiratory inflammation in BA and is informative in assessment of effectiveness of the basic therapy. In moderate BA children on flixotide and tailed were the first to achieve normal NO secretion in the airways.
Nevzorova
V A
VA
Prosekova
E V
EV
Gel'tser
B I
BI
Luk'ianov
P A
PA
Shestovskaia
T N
TN
Maĭstrovskaia
Iu V
IuV
Arzamastseva
A I
AI
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D015415:Biomarkers; D001944:Breath Tests; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000378:metabolism; D007665:Ketotifen / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D017835:Nedocromil / Q000008:administration & dosage / Q000627:therapeutic use; D009569:Nitric Oxide / Q000378:metabolism*; D013997:Time Factors
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D017835:Nedocromil; D009569:Nitric Oxide; D000068298:Fluticasone; D004205:Cromolyn Sodium; D007665:Ketotifen